The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Open accessAbstract
For the adoptive transfer of tumor-directed T lymphocytes to prove effective, there will probably need to be a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express. The Reed-Stemberg cells of Hodgkin lymphoma (HL) predominantly produce thymus- and activation-regulated chemokine/CC chemokine ligand 17 (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22), which preferentially attract type 2 T helper (Th2) cells and regulatory T cells (Tregs) that express the TARC/MDC-specific chemokine receptor CCR4, thus generating an immunosuppressed tumor environment. By contrast, effector CD8(+) T cells lack CCR4, are nonresponsive to these chemokines and are rarely detected at the tumor site. We now show that forced expression of CCR4 by effector T cells enhances their migration to HL cells. Furthermore, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated antigen CD30 sustain their cytotoxic function and cytokine secretion in vitro, and produce enhanced tumor control when infused intravenously in mice engrafted with human HL. This approach may be of value in patients affected by HL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The preclinical model of murine Hodgkin tumor with T cells coexpressing CCR4 and a chimeric antigen receptor targeting CD30 demonstrated an improved homing and antitumor activity [369].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [369]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationPule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Iellem, A., Mariani, M., Lang, R., Recalde, H., Panina-Bordignon, P., Sinigaglia, F., & D'Ambrosio, D. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.847 · Cited by 914
Huerta, G. T., & Villasana, J. E. M. (1988) · PubMed · Cited by 804
Chemokines and the Tissue-Specific Migration of Lymphocytes
Kunkel, E. J., & Butcher, E. C. (2002) · Immunity · doi:10.1016/s1074-7613(01)00261-8 · Cited by 689
Orchestrating the orchestrators: chemokines in control of T cell traffic
Bromley, S. K., Mempel, T. R., & Luster, A. D. (2008) · Nature Immunology · doi:10.1038/ni.f.213 · Cited by 593
Reiss, Y., Proudfoot, A. E., Power, C. A., Campbell, J. J., & Butcher, E. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.10.1541 · Cited by 517
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Marshall, N. A., Christie, L. E., Munro, L. R., Culligan, D. J., Johnston, P. W., Barker, R. N., & Vickers, M. A. (2004) · Blood · doi:10.1182/blood-2003-07-2594 · Cited by 509
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Self-citation
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
“Some work has indicated that introduction of chemokine receptors into CAR T cells can improve their trafficking to tumors that produce the cognate chemokines (Di Stasi et al., 2009; Moon et al., 2011).”
BackgroundIL-35-mediated induction of a potent regulatory T cell population
Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P. R., Guy, C., Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1952 · Cited by 869
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Metadata
- Authors
- Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B.
- Affiliations
- Center for Cell and Gene Therapy and
- Houston Methodist (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-06-18
- Volume
- 113
- Issue
- 25
- Pages
- 6392-6402
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2710932
- OpenAlex
- W2076668490
- Cited by
- 533
- References
- 37
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 23 · 2023: 44 · 2022: 41 · 2021: 48 · 2020: 52 · 2019: 44 · 2018: 40 · 2017: 36 · 2016: 30 · 2015: 22 · 2014: 26 · 2013: 24 · 2012: 12
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Doris Duke Charitable Foundation
- American-Italian Cancer Foundation
- National Institutes of Health
- National Cancer Institute (R01CA131027, P50CA126752)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- Hodgkin's disease, CCR4, chimeric antigen receptor, CD30, T cell homing, TARC/CCL17, MDC/CCL22, chemokine receptors, adoptive T cell therapy, CD8+ T cells, tumor immunosuppression, anticancer activity
- MeSH terms
- Animals, Chemotaxis, Leukocyte, Cytotoxicity, Immunologic, Genetic Vectors, Hodgkin Disease, Humans, Lymphocyte Activation, Recombinant Fusion Proteins, Transduction, Genetic, T-Lymphocyte Subsets, Receptors, Lymphocyte Homing, Mice, SCID, Reed-Sternberg Cells, Lymphoma, Large-Cell, Anaplastic, Ki-1 Antigen, Th2 Cells, Adoptive Transfer, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Receptors, CCR4, Chemokine CCL17, Chemokine CCL22
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. https://app.cochat.ai/papers/10.1182/blood-2009-03-209650
- The paper
- Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009). T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. https://doi.org/10.1182/blood-2009-03-209650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.